Business Context and Reporting Period
This Form 8-K filing by Flotek Industries, Inc. (FTK) covers events occurring on June 6 and June 7, 2023. The report details significant corporate governance changes, including executive leadership transitions, the results of the annual stockholder meeting, and new executive compensation agreements.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and personnel matters.
Material Changes and Executive Actions
- CEO Appointment: Dr. Ryan Ezell was appointed Chief Executive Officer and a member of the Board of Directors, effective June 6 and June 8, 2023, respectively. He succeeds Harsha V. Agadi, who ceased serving as Interim CEO but remains on the Board as Non-Executive Chairman.
- Executive Compensation: Dr. Ezell's employment agreement includes a $550,000 annual base salary and a target annual bonus of 100% of base salary. Severance provisions include 18 months' base salary and equity acceleration in the event of termination for convenience, Good Reason, or Change of Control.
- CFO Equity Grant: Bond Clement, Chief Financial Officer, was granted an option to purchase 371,901 shares at $0.62 per share. Vesting is contingent on the stock price reaching an average of $3.00 per share over 30 consecutive trading days.
Stockholder Meeting Results and Governance
At the annual meeting on June 7, 2023, 63.08% of outstanding shares were represented. Key voting outcomes included:
- Director Elections: All six director candidates were elected.
- Executive Compensation: The advisory vote on named executive officer compensation was approved.
- Auditor Ratification: KPMG, LLP was ratified as the independent auditor for 2023.
- Pre-funded Warrant: Stockholders did not approve the issuance of common stock underlying the pre-funded warrant held by ProFrac Holdings II, LLC.
- Incentive Plan: Amendments to the 2018 Long-Term Incentive Plan were approved.
Investor Verification Checklist
- Verify the full text of Dr. Ezell's employment agreement (Exhibit 10.1) for specific definitions of "Good Reason" and "Change of Control."
- Review the implications of the stockholder rejection of the ProFrac Holdings II, LLC pre-funded warrant issuance.
- Monitor the company's stock price performance relative to the $3.00 vesting threshold for the CFO's stock options.
- Confirm the transition timeline for Dr. Ezell's role as CEO and Mr. Agadi's transition to Non-Executive Chairman.